Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir

Table 1

Patients’ baseline characteristics ().

Age (years) (range)	47 (30–65)
Body weight (kg)	64.5 (45.0–110.5)
Body mass index (kg/m^2)	23.2 (17.9–32.3)
Prior interferon therapy	7 (30%)
History of HCC treatment	6 (26%)
Genotype B/C	2 (9%)/21 (91%)
Duration of prior entecavir (days)	1379 (371–2410)
HBe Ag positive	8 (35%)
HBV-DNA (log IU/mL)	2.1 (0–2.4)
HBs Ag (IU/mL)	1361.77 (112.40–19673.70)
Liver cirrhosis (%)	11 (48)
IL28B (rs8099917) major	20 (87)
White blood cell (/mm^3)	4870 (2920–9100)
Hemoglobin (g/dL)	14.8 (12.0–16.5)
Platelets (×10^4/mm^3)	17.8 (9.3–28.4)
ALT (IU/L)	21 (10–47)
GTP (IU/L)	24 (11–82)
Alpha-fetoprotein (ng/mL)	2.2 (1–6.9)
Type IV collagen 7S (ng/mL)	3.8 (2.5–5.4)
Hyaluronic acid (ng/mL)	48 (10–266)

HCC, hepatocellular carcinoma; HBe Ag, hepatitis B e antigen, HBs Ag, hepatitis B surface antigen; HBV, hepatitis B virus; IL, interleukin; ALT, alanine aminotransferase; GTP, -glutamyltransferase.
Values are expressed as medians (range) or numbers of patients (percent).